<DOC>
	<DOCNO>NCT01690299</DOCNO>
	<brief_summary>This study test clinical effectiveness safety apremilast compare placebo well etanercept compare placebo group patient moderate severe plaque psoriasis . Apremilast ( CC-10004 ) new oral agent clinical development treatment inflammatory autoimmune disorder , psoriatic arthritis , psoriasis , rheumatoid arthritis , Behçet disease . Etanercept approve treatment psoriasis ; widely prescribed anti-tumor necrosis factor ( TNF ) psoriasis .</brief_summary>
	<brief_title>Phase 3b Safety Efficacy Study Apremilast Treat Moderate Severe Plaque-plaque Psoriasis</brief_title>
	<detailed_description>This phase 3b , multicenter , randomize , placebo-controlled , double-blind , double-dummy , study efficacy safety apremilast , etanercept , placebo , subject moderate severe plaque psoriasis . Approximately 240 subject randomize 1:1:1 three treatment group . All subject receive tablet injection Week 16 . The study consist four phase : - Screening Phase - 35 day - Double-blind Placebo-controlled Phase - Weeks 0-16 - Apremilast Extension Phase - Weeks 16-104 - Post-treatment Observational Follow-up Phase During double-blind , placebo-controlled phase , subject receive treatment one following : - apremilast ( APR ) 30 mg tablet orally twice day ( BID ) plus weekly ( QW ) evaluator/subject-blinded subcutaneous ( SC ) saline ( placebo ) injection ( 1 mL x 2 injection SC ) , - etanercept ( ETN ) 50 mg evaluator/subject-blinded subcutaneous ( SC ) weekly ( QW ) injection ( 2 x 25 mg ) plus placebo tablet orally twice day ( BID ) , - placebo tablet evaluator/subject-blinded subcutaneous ( SC ) saline ( placebo ) injection . All subject ask participate 4-week Post-treatment Observational Follow-up Phase either upon completion study upon discontinuation investigational product subject terminate study early .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Males female , ≥ 18 year age Diagnosis chronic , moderate severe plaque psoriasis least 12 month prior Screening , candidate phototherapy and/or systemic ( include etanercept ) therapy Had inadequate response , intolerance , contraindication least 1 conventional systemic agent treatment psoriasis . No prior exposure biologics treatment psoriatic arthritis psoriasis Other psoriasis , history clinically significant uncontrolled systemic disease ; condition , include presence laboratory abnormality , would place subject unacceptable risk he/she participate study . Pregnant breast feeding . Have fail 3 systemic agent treatment psoriasis . History allergy component investigational product ( IP ) , include human immunoglobulin ( Ig ) proteins allergy etanercept . Hepatitis B surface antigen antihepatitis C antibody positive Screening . Latent , active tuberculosis ( TB ) inadequately treated TB ; nontuberculous mycobacterial infection opportunistic infection ( eg , cytomegalovirus , Pneumocystis carinii , aspergillosis , Clostridium difficile ) . Have history , ongoing , chronic recurrent infectious disease Have receive , expect receive , live virus bacterial vaccination within 3 month first administration IP , Week 20 study . Had Bacillus CalmetteGuérin ( BCG ) vaccination within 1 year prior screen . History positive human immunodeficiency virus ( HIV ) , congenital acquire immunodeficiency ( eg , common variable immunodeficiency disease ) . Active substance abuse history substance abuse within 6 month prior Screening . Malignancy history malignancy , except treat [ ie , cure ] basal cell squamous cell situ skin carcinoma cervical intraepithelial neoplasia [ CIN ] carcinoma situ cervix evidence recurrence within previous 5 year . Psoriasis flare rebound within 4 week prior Screening . Topical therapy within 2 week randomization systemic therapy psoriasis within 4 week prior randomization Use phototherapy within 4 week prior randomization prolong sun exposure use tan booth ultraviolet ( UV ) light source . Any investigational drug within 4 week prior randomization , 5 pharmacokinetic/pharmacodynamic half life , know ( whichever longer ) . Prior treatment apremilast etanercept .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>arthritis</keyword>
	<keyword>psoriatic</keyword>
	<keyword>palmoplantar</keyword>
	<keyword>scalp</keyword>
	<keyword>psoriasis pill</keyword>
	<keyword>psoriasis tablet</keyword>
	<keyword>plaque psoriasis</keyword>
	<keyword>plaque type psoriasis</keyword>
	<keyword>moderate severe plaque type psoriasis</keyword>
	<keyword>psoriatic arthritis</keyword>
</DOC>